Phase I evaluation of XL019, an oral, potent, and selective JAK2 inhibitor

Srdan Verstovsek, Constantine S. Tam, Martha Wadleigh, Lubomir Sokol, Catherine C. Smith, Lynne A. Bui, Chunyan Song, Douglas O. Clary, Patrycja Olszynski, Jorge Cortes, Hagop Kantarjian, Neil P. Shah

Research output: Contribution to journalArticlepeer-review

41 Scopus citations

Fingerprint

Dive into the research topics of 'Phase I evaluation of XL019, an oral, potent, and selective JAK2 inhibitor'. Together they form a unique fingerprint.

Medicine & Life Sciences